Paolo Tarantino/X
Jun 1, 2025, 04:10
Paolo Tarantino: Impressive Phase 2 Data with the Trop2 ADC Sac-TMT for 1L mTNBC at ASCO 2025
Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, shared a post on X:
“Impressive phase 2 data with the Trop2 ADC Sac-TMT for 1L mTNBC (n=41): ORR 70%, mPFS 13.4 months.
High activity irrespective of PDL1 expression. Same setting of ASCENT-03/04.
Confirms the feeling that, in the future, we’ll treat mTNBC with frontline Trop2 ADCs.”
More posts featuring ASCO 2025 on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 2, 2025, 15:40
Jun 2, 2025, 15:37
Jun 2, 2025, 15:20
Jun 2, 2025, 14:49
Jun 2, 2025, 13:13